NASDAQ:REVB

Revelation Biosciences (REVB) Stock Price, News & Analysis

Revelation Biosciences logo
$3.97 +0.09 (+2.27%)
Closing price 03:58 PM Eastern
Extended Trading
$3.93 -0.04 (-1.03%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Revelation Biosciences Stock (NASDAQ:REVB)

Advanced

Key Stats

Today's Range
$3.60
▼
$4.23
50-Day Range
$3.29
▼
$6.97
52-Week Range
$3.08
▼
$40.60
Volume
13,066 shs
Average Volume
14,591 shs
Market Capitalization
$2.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Revelation Biosciences is a clinical-stage biotechnology company developing treatments that target the innate immune system. Its research focuses on potential therapies for infectious and other diseases.

The company’s lead program, Gemini, is an intranasal formulation of an immune-stimulating compound designed to activate Toll-like receptor 4. Revelation has investigated Gemini as a potential way to help prevent or treat respiratory infections.

Revelation’s work is centered on developing its therapeutic candidates; the company has not established a broad commercial product portfolio. Its programs remain in development.

AI Generated. May Contain Errors.

Revelation Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
16th Percentile Overall Score

REVB MarketRank™: 
0.775803607755 of 5 stars

Revelation Biosciences scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Revelation Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Revelation Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Revelation Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Revelation Biosciences are expected to grow in the coming year, from ($24.53) to ($11.54) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Revelation Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Revelation Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Revelation Biosciences has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.96% of the float of Revelation Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Revelation Biosciences has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Revelation Biosciences has recently increased by 93.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Revelation Biosciences does not currently pay a dividend.

  • Dividend Growth

    Revelation Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Revelation Biosciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Revelation Biosciences this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Revelation Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.80% of the stock of Revelation Biosciences is held by insiders.

  • Percentage Held by Institutions

    12.80% of the stock of Revelation Biosciences is held by institutions.

  • Read more about Revelation Biosciences' insider trading history.
Receive REVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

REVB Stock News Headlines

Research Analysts Offer Predictions for REVB FY2026 Earnings
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Analysts Set Expectations for REVB Q1 Earnings
See More Headlines

REVB Stock Analysis - Frequently Asked Questions

Revelation Biosciences' stock was trading at $22.3944 on January 1st, 2026. Since then, REVB shares have decreased by 82.3% and is now trading at $3.9680.

Revelation Biosciences, Inc. (NASDAQ:REVB) issued its earnings results on Thursday, November, 5th. The company reported ($5.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.16) by $0.24.

Revelation Biosciences shares reverse split before market open on Tuesday, January 28th 2025.The 1-16 reverse split was announced on Friday, January 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revelation Biosciences investors own include NVIDIA (NVDA), SoundHound AI (SOUN), Amprius Technologies (AMPX), BigBear.ai (BBAI), Advanced Micro Devices (AMD), Aridis Pharmaceuticals (ARDS) and Blink Charging (BLNK).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:REVB
CIK
1810560
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($42.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.91 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-124.23%
Return on Assets
-98.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.98
Quick Ratio
3.98

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.59 per share
Price / Book
0.37

Miscellaneous

Outstanding Shares
680,000
Free Float
650,000
Market Cap
$2.70 million
Optionable
Not Optionable
Beta
-0.13
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:REVB) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners